A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
Julie N. Graff(Seattle Cancer Care Alliance), Amy E. Moran(Oregon Health & Science University)
Cited by 120
Related Papers
T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse
|The Journal of Experimental Medicine|2011|1k
Apc Deficiency Is Associated with Increased Egfr Activity in the Intestinal Enterocytes and Adenomas of C57BL/6J-Min/+ Mice
|Journal of Biological Chemistry|2004|111